Thermo Fisher introduces cell therapy workflow media

By The Science Advisory Board staff writers

January 27, 2021 -- Thermo Fisher Scientific has launched a new medium of the first human T lymphocytes (T cells) specifically designed for allogeneic cell therapy workflows.

The Gibco CTS OpTmizer Pro Serum Free Media (SFM) targets the metabolism of healthy donor cells, making it well-suited for use in the production of allogeneic, off-the-shelf cell therapies. The serum free media is compatible with automated and longer workflows and is suited for a closed system. SFM enhances donor T-cell proliferation, maintains central memory T cells further into expansion, and delays effector differentiation of healthy donor T cells, according to the company.

Thermo Fisher closes Henogen acquisition
Thermo Fisher Scientific has closed its acquisition of Groupe Novasep's Henogen, a viral vector manufacturing business in Belgium, for approximately 725 million...
Thermo Fisher subsidizes more sequencers for global coronavirus research
Thermo Fisher Scientific is expanding a global SARS-CoV-2 program that provides its next-generation sequencers at subsidized prices to help analyze new...
Thermo Fisher launches managed equipment plan
Thermo Fisher Scientific has launched a new subscription-based program called Managed Equipment Solutions that combines instrument and equipment sales...
Thermo Fisher acquires Phitonex
Thermo Fisher Scientific has completed its acquisition of Phitonex, a North Carolina-based company that has created a spectral dye platform for high-resolution...
Thermo Fisher expands plasmid manufacturing capabilities
Thermo Fisher Scientific announced it will build a new plasmid DNA manufacturing facility in Carlsbad, CA.

Copyright © 2021

Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter